【汇丰：上调中国生物制药目标价34% 维持“买入”评级】金十数据6月4日讯，汇丰发报告指，上调中国生物制药(01177.HK)目标价34%，从3.8港元升至5.1港元，维持“买入”评级。汇丰认为，中国生物制药在2025年ASCO大会上公布的的数据令人鼓舞，因此对其创新药的销售前景更加乐观，2025及2026年经调整净利润预测分别上调39%和45%。展望未来，该行该公司在2025—2027年实现两位数获利增长的能力更加乐观，这得益于PD—L1和G—CSF的销售增长快于预期、新药上市及营运效率的提升。该公司股价今年迄今上涨36%。由于该行业正在进行多项商业拓展，行业情绪有所改善。因此认为该公司目前的估值具有吸引力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.